- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT06172296
- Ursprunglig rättegång
Dinutuximab med kemoterapi, kirurgi och stamcellstransplantation för behandling av barn med nydiagnostiserade högriskneuroblastom
En fas 3-studie av dinutuximab tillagd till intensiv multimodal terapi för barn med nydiagnostiserade högriskneuroblastom
This phase III trial tests how well the addition of dinutuximab to Induction chemotherapy along with standard of care surgical resection of the primary tumor, radiation, stem cell transplantation, and immunotherapy works for treating children with newly diagnosed high-risk neuroblastoma. Dinutuximab is a monoclonal antibody that binds to a molecule called GD2, which is found on the surface of neuroblastoma cells, but is not present on many healthy or normal cells in the body. When dinutuximab binds to the neuroblastoma cells, it helps signal the immune system to kill the tumor cells. This helps the cells of the immune system kill the cancer cells, this is a type of immunotherapy. When chemotherapy and immunotherapy are given together, during the same treatment cycle, it is called chemoimmunotherapy. This clinical trial randomly assigns patients to receive either standard chemotherapy and surgery or chemoimmunotherapy (chemotherapy plus dinutuximab) and surgery during Induction therapy. Chemotherapy drugs administered during Induction include, cyclophosphamide, topotecan, cisplatin, etoposide, vincristine, and doxorubicin. These drugs work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing or by stopping them from spreading. Upon completion of 5 cycles of Induction therapy, a disease evaluation is completed to determine how well the treatment worked. If the tumor responds to therapy, patients receive a tandem transplantation with stem cell rescue. If the tumor has little improvement or worsens, patients receive chemoimmunotherapy on Extended Induction. During Extended Induction, dinutuximab is given with irinotecan, temozolomide. Patients with a good response to therapy move on to Consolidation therapy, when very high doses of chemotherapy are given at two separate points to kill any remaining cancer cells. Following, transplant, radiation therapy is given to the site where the cancer originated (primary site) and to any other areas that are still active at the end of Induction. The final stage of therapy is Post-Consolidation. During Post-Consolidation, dinutuximab is given with isotretinoin, with the goal of maintaining the response achieved with the previous therapy. Adding dinutuximab to Induction chemotherapy along with standard of care surgical resection of the primary tumor, radiation, stem cell transplantation, and immunotherapy may be better at treating children with newly diagnosed high-risk neuroblastoma.
Studieöversikt
Status
Betingelser
Intervention / Behandling
- Läkemedel: Carboplatin
- Läkemedel: Cyclophosphamide
- Läkemedel: Cisplatin
- Procedur: Bone Marrow Biopsy
- Läkemedel: Doxorubicin
- Läkemedel: Vincristine
- Procedur: Magnetic Resonance Imaging
- Procedur: Echocardiography Test
- Procedur: Multigated Acquisition Scan
- Procedur: Bone Marrow Aspiration
- Läkemedel: Etoposide
- Procedur: Computed Tomography
- Läkemedel: Topotecan
- Strålning: Radiation Therapy
- Procedur: Biospecimen Collection
- Övrig: Survey Administration
- Läkemedel: Melphalan
- Läkemedel: Irinotecan
- Läkemedel: Thiotepa
- Biologisk: Dinutuximab
- Procedur: FDG-Positron Emission Tomography and Computed Tomography Scan
- Procedur: Hematopoietic Cell Transplantation
- Läkemedel: Isotretinoin
- Procedur: Leukapheresis
- Procedur: Radionuclide Imaging
- Läkemedel: Temozolomide
- Procedur: Tumor Resection
Detaljerad beskrivning
PRIMARY OBJECTIVE:
I. To determine if the event-free survival (EFS) of patients with newly diagnosed high-risk neuroblastoma assigned to early chemoimmunotherapy during Induction differs from that of patients who are not assigned to treatment that includes early chemoimmunotherapy.
SECONDARY OBJECTIVES:
I. To determine if early chemoimmunotherapy during Induction therapy improves end of Induction (EOI) response rates and overall survival (OS) for patients with newly diagnosed high-risk neuroblastoma.
II. To determine response rates, EFS, and OS following an Extended Induction regimen with chemoimmunotherapy in patients with progressive disease or a poor response to Induction therapy.
III. To compare the toxicities experienced by patients treated with chemoimmunotherapy during Induction versus those experienced by patients treated with standard Induction and to describe toxicities experienced during Extended Induction.
IV. To determine GD2 expression on tumor tissue and tumor cells in bone marrow and assess for associations with response and outcome.
EXPLORATORY OBJECTIVES:
I. To describe the association between tumor and host factors and outcomes in patients receiving protocol therapy.
II. To evaluate circulating biomarkers and markers of minimal residual disease at baseline and during therapy, and assess for associations with response and outcome.
III. To compare patterns of failure between patients treated with and without dinutuximab during induction.
IV. To determine the effect of telomere maintenance mechanisms on end of Induction response rates, EFS, and OS.
V. To explore the impact of high-risk neuroblastoma (HRNBL) and its therapy, including the addition of dinutuximab to Induction chemotherapy, on functional and quality of life outcomes in patients with HRNBL, as measured by caregiver (parent/legal guardian) and patient questionnaires.
VI. To describe the adequacy of diagnostic biopsy specimens, including those obtained by percutaneous core needle biopsy.
VII. To explore the associations between family-reported adverse social determinants of health and both clinical outcomes and biology.
VIII. To develop and validate deep learning predictors of Induction response based on diagnostic MIBG scans. (Imaging Objective) IX. To compare institutional versus central determination of overall response, individual response components (primary tumor, soft tissue and bone metastatic disease, and bone marrow metastatic disease), and poor end of induction response (PEIR) and good end of induction response (GEIR) determination. (Imaging Objective) X. To describe late toxicities (including impaired organ function, neuropsychiatric toxicity, and incidence of secondary malignancy) in patients treated with dinutuximab during Induction or Extended Induction to late toxicities in patients who have not received dinutuximab during these phases of therapy.
XI. To evaluate whether reduced dose radiotherapy to the primary site clinical target volume (CTV) in patients with complete response of the primary site at EOI results in comparable local control relative to historical cohorts.
XII. To compare post-transplant complications between treatment arms, and assess for associations with outcome.
XIII. To assess for associations between EOI response (including good end of Induction response [GEIR] and poor end of Induction response [PEIR]) and individual response components (primary tumor, soft tissue and bone metastatic disease, and bone marrow metastatic disease) with outcome (EFS and OS).
XIV. To describe and compare the changes in image-defined risk factors (IDRFs) between patients treated with and without dinutuximab during Induction and associate with surgical outcomes and local failure rates following primary tumor resection.
XV. To bank serial samples of blood, bone marrow, and tumor tissue for future research.
OUTLINE: Patients receive Induction cycle 1 and are then randomized to 1 of 2 treatment arms.
INDUCTION CYCLE 1: Patients receive cyclophosphamide intravenously (IV) over 30 minutes and topotecan IV over 30 minutes on days 1-5 in the absence of unacceptable toxicity.
ARM A:
INDUCTION CYCLES 2-5: Patients receive cyclophosphamide IV over 30 minutes and topotecan IV over 30 minutes on days 1-5 of cycle 2 in the absence of unacceptable toxicity. Patients then undergo stem cell harvest via apheresis. Patients then receive cisplatin IV over 4 hours and etoposide IV over 2 hours on days 1-3 of cycles 3 and 5, and vincristine IV on day 1, doxorubicin IV over 15 minutes, and cyclophosphamide IV over 1 hour on days 1-2 of cycle 4 in the absence of unacceptable toxicity. Patients undergo primary tumor resection after Induction cycle 4 or 5. Following Induction cycle 5, patients undergo testing to determine response to Induction therapy. Patients with a good tumor response proceed to Consolidation, while patients with a poor tumor response proceed to Extended Induction.
EXTENDED INDUCTION: Patients with a poor tumor response or progression during Induction receive temozolomide orally (PO), via nasogastric tube (NG), or via gastric tube (G-tube) on days 1-5, irinotecan IV over 90 minutes on days 1-5, and dinutuximab IV over 10 hours. Treatment repeats every 21 days for up to a maximum of 6 cycles in the absence of disease progression or unacceptable toxicity. If at any time during Extended Induction testing shows a good tumor response, patients proceed to Consolidation. If after 6 cycles of Extended Induction or if at any time progression is noted, patients are removed from the study.
CONSOLIDATION: Patients undergo two autologous hematopoietic stem cell transplantations (HSCTs) during Consolidation. Patients receive thiotepa IV over 2 hours on days -7 to -5 and cyclophosphamide IV over 1 hour on days -5 to -2 during HSCT 1. Patients then receive stem cell infusion IV on day 0. Between 6 and 10 weeks after stem cell infusion, patients receive melphalan IV over 30 minutes on days -7 to -5, etoposide IV over 24 hours on days -7 to -4, and carboplatin over 24 hours on days -7 to -4 during HSCT 2. Patients receive stem cell infusion IV on day 0. Between day +42 and day +80 after HSCT 2. Patients receive radiation daily for 12 treatments in the absence of disease progression or unacceptable toxicity.
POST CONSOLIDATION: Patients receive dinutuximab IV over 10 hours on days 4-7 and isotretinoin PO twice daily (BID) on days 11-24 of cycles 1-5. Treatment repeats every 28 days for up to 5 cycles in the absence of disease progression or unacceptable toxicity. Patients then receive isotretinoin PO BID on days 15-28 for 1 additional cycle, cycle 6.
Patients undergo blood and urine sample collection, echocardiogram (ECHO) or multigated acquisition scan (MUGA), bone marrow aspiration and/or biopsy, computed tomography (CT) scan, magnetic resonance imaging (MRI), iodine-123 meta-iodobenzylguanidine (I-MIBG) scan and possible fluorodeoxyglucose position emission tomography (FDG-PET) scan throughout the study.
ARM B:
INDUCTION CYCLES 2-5: Patients receive cyclophosphamide IV over 30 minutes, topotecan IV over 30 minutes on days 1-5, and dinutuximab IV over 10 hours on days 2-5 of cycle 2 in the absence of unacceptable toxicity. Patients then undergo stem cell harvest via apheresis. Patients receive cisplatin IV over 4 hours and etoposide IV over 2 hours on days 1-3 and dinutuximab IV over 10 hours on days 2-5 of cycles 3 and 5, and vincristine IV on day 1, doxorubicin IV over 15 minutes, and cyclophosphamide IV over 1 hour on days 1-2, and dinutuximab IV over 10 hours on days 2-5 of cycle 4 in the absence of unacceptable toxicity. Patients undergo primary tumor resection after Induction cycle 4 or 5. Following Induction cycle 5, patients undergo testing to determine response to Induction therapy. Patients with a good tumor response proceed to Consolidation, while patients with a poor tumor response proceed to Extended Induction.
EXTENDED INDUCTION: Patients with a poor tumor response or progression during Induction receive temozolomide PO, via NG tube, or via G-tube on days 1-5, irinotecan IV over 90 minutes on days 1-5, and dinutuximab IV over 10 hours. Treatment repeats every 21 days for up to a maximum of 6 cycles in the absence of disease progression or unacceptable toxicity. If at any time during Extended Induction testing shows a good tumor response, patients proceed to Consolidation. If after 6 cycles of Extended Induction or if at any time progression is noted, patients are removed from the study.
CONSOLIDATION: Patients undergo two autologous HSCTs during Consolidation. Patients receive thiotepa IV over 2 hours on days -7 to -5 and cyclophosphamide IV over 1 hour on days -5 to -2 during HSCT 1. Patients then receive stem cell infusion IV on day 0. Between 6 and 10 weeks after stem cell infusion patients receive melphalan IV over 30 minutes on days -7 to -5, etoposide IV over 24 hours on days -7 to -4, and carboplatin over 24 hours on days -7 to -4 during HSCT 2. Patients receive stem cell infusion IV on day 0. Between day +42 and day +80 after HSCT 2, patients receive radiation daily for 12 treatments in the absence of disease progression or unacceptable toxicity.
POST CONSOLIDATION: Patients receive dinutuximab IV over 10 hours on days 4-7 and isotretinoin PO BID on days 11-24 of cycles 1-5. Treatment repeats every 28 days for up to 5 cycles in the absence of disease progression or unacceptable toxicity. Patients then receive isotretinoin PO BID on days 15-28 for 1 additional cycle, cycle 6.
Patients undergo blood and urine sample collection, ECHO or MUGA, bone marrow aspiration and/or biopsy, CT scan, MRI, I-MIBG scan and possible FDG-PET scan throughout the study.
After completion of study treatment, patients are followed up at 3, 6, 9,12, 15, 18, 24, 30, 36, 42, 48, 54, and 60 months and then periodically for up to 10 years from enrollment.
Studietyp
Inskrivning (Beräknad)
Fas
- Fas 3
Kontakter och platser
Studieorter
-
-
New South Wales
-
Randwick, New South Wales, Australien, 2031
- Rekrytering
- Sydney Children's Hospital
-
Huvudutredare:
- Draga Barbaric
-
Kontakt:
- Site Public Contact
- Telefonnummer: (02) 9382-1721
-
Westmead, New South Wales, Australien, 2145
- Rekrytering
- The Children's Hospital at Westmead
-
Kontakt:
- Site Public Contact
- Telefonnummer: 61-2-9845 1400
-
Huvudutredare:
- Bhavna Padhye
-
-
Queensland
-
South Brisbane, Queensland, Australien, 4101
- Rekrytering
- Queensland Children's Hospital
-
Huvudutredare:
- Steven A. Foresto
-
Kontakt:
- Site Public Contact
- Telefonnummer: 61 7 3068 1111
-
-
Victoria
-
Parkville, Victoria, Australien, 3052
- Rekrytering
- Royal Children's Hospital
-
Huvudutredare:
- Martin A. Campbell
-
Kontakt:
- Site Public Contact
- Telefonnummer: 61 3 9345 5656
- E-post: Jordan.Hansford@rch.org.au
-
-
Western Australia
-
Perth, Western Australia, Australien, 6009
- Rekrytering
- Perth Children's Hospital
-
Kontakt:
- Site Public Contact
- E-post: helpdesk@childrensoncologygroup.org
-
Huvudutredare:
- Michelle Ng
-
-
-
-
Alabama
-
Birmingham, Alabama, Förenta staterna, 35233
- Rekrytering
- Children's Hospital of Alabama
-
Kontakt:
- Site Public Contact
- Telefonnummer: 205-638-9285
- E-post: oncologyresearch@peds.uab.edu
-
Huvudutredare:
- Elizabeth D. Alva
-
Mobile, Alabama, Förenta staterna, 36604
- Rekrytering
- USA Health Strada Patient Care Center
-
Kontakt:
- Site Public Contact
- Telefonnummer: 800-388-8721
-
Huvudutredare:
- Hamayun Imran
-
-
Arizona
-
Mesa, Arizona, Förenta staterna, 85202
- Rekrytering
- Banner Children's at Desert
-
Kontakt:
- Site Public Contact
- Telefonnummer: 480-412-3100
-
Huvudutredare:
- Joseph C. Torkildson
-
Phoenix, Arizona, Förenta staterna, 85016
- Rekrytering
- Phoenix Childrens Hospital
-
Kontakt:
- Site Public Contact
- Telefonnummer: 602-546-0920
-
Huvudutredare:
- Alok K. Kothari
-
Tucson, Arizona, Förenta staterna, 85719
- Rekrytering
- Banner University Medical Center - Tucson
-
Kontakt:
- Site Public Contact
- E-post: UACC-IIT@uacc.arizona.edu
-
Huvudutredare:
- Monica M. Davini
-
-
Arkansas
-
Little Rock, Arkansas, Förenta staterna, 72202-3591
- Rekrytering
- Arkansas Children's Hospital
-
Huvudutredare:
- Michael W. Bishop
-
Kontakt:
- Site Public Contact
- Telefonnummer: 501-364-7373
-
-
California
-
Downey, California, Förenta staterna, 90242
- Rekrytering
- Kaiser Permanente Downey Medical Center
-
Kontakt:
- Site Public Contact
- Telefonnummer: 626-564-3455
-
Huvudutredare:
- Robert M. Cooper
-
Duarte, California, Förenta staterna, 91010
- Rekrytering
- City of Hope Comprehensive Cancer Center
-
Kontakt:
- Site Public Contact
- Telefonnummer: 800-826-4673
- E-post: becomingapatient@coh.org
-
Huvudutredare:
- Hung C. Tran
-
Loma Linda, California, Förenta staterna, 92354
- Rekrytering
- Loma Linda University Medical Center
-
Kontakt:
- Site Public Contact
- Telefonnummer: 909-558-4050
-
Huvudutredare:
- Albert Kheradpour
-
Long Beach, California, Förenta staterna, 90806
- Rekrytering
- Miller Children's and Women's Hospital Long Beach
-
Kontakt:
- Site Public Contact
- Telefonnummer: 562-933-5600
-
Huvudutredare:
- Jacqueline N. Casillas
-
Los Angeles, California, Förenta staterna, 90027
- Rekrytering
- Children's Hospital Los Angeles
-
Kontakt:
- Site Public Contact
- Telefonnummer: 323-361-4110
-
Huvudutredare:
- Araz Marachelian
-
Los Angeles, California, Förenta staterna, 90048
- Rekrytering
- Cedars-Sinai Medical Center
-
Huvudutredare:
- Fataneh (Fae) Majlessipour
-
Kontakt:
- Site Public Contact
- Telefonnummer: 310-423-2133
- E-post: Cancer.trial.info@cshs.org
-
Los Angeles, California, Förenta staterna, 90095
- Rekrytering
- Mattel Children's Hospital UCLA
-
Kontakt:
- Site Public Contact
- Telefonnummer: 310-825-6708
-
Huvudutredare:
- Satiro N. De Oliveira
-
Madera, California, Förenta staterna, 93636
- Rekrytering
- Valley Children's Hospital
-
Kontakt:
- Site Public Contact
- Telefonnummer: 559-353-3000
- E-post: Research@valleychildrens.org
-
Huvudutredare:
- Ruetima Titapiwatanakun
-
Oakland, California, Förenta staterna, 94611
- Rekrytering
- Kaiser Permanente-Oakland
-
Kontakt:
- Site Public Contact
- Telefonnummer: 877-642-4691
- E-post: Kpoct@kp.org
-
Huvudutredare:
- Aarati V. Rao
-
Oakland, California, Förenta staterna, 94609
- Rekrytering
- UCSF Benioff Children's Hospital Oakland
-
Huvudutredare:
- Jennifer G. Michlitsch
-
Kontakt:
- Site Public Contact
- Telefonnummer: 510-428-3264
- E-post: PedOncRschOAK@ucsf.edu
-
Orange, California, Förenta staterna, 92868
- Rekrytering
- Children's Hospital of Orange County
-
Kontakt:
- Site Public Contact
- Telefonnummer: 714-509-8646
- E-post: oncresearch@choc.org
-
Huvudutredare:
- Elyssa M. Rubin
-
Palo Alto, California, Förenta staterna, 94304
- Rekrytering
- Lucile Packard Children's Hospital Stanford University
-
Kontakt:
- Site Public Contact
- Telefonnummer: 800-694-0012
- E-post: ccto-office@stanford.edu
-
Huvudutredare:
- Jay Michael S. Balagtas
-
Sacramento, California, Förenta staterna, 95817
- Rekrytering
- University of California Davis Comprehensive Cancer Center
-
Kontakt:
- Site Public Contact
- Telefonnummer: 916-734-3089
-
Huvudutredare:
- Marcio H. Malogolowkin
-
Sacramento, California, Förenta staterna, 95816
- Rekrytering
- Sutter Medical Center Sacramento
-
Kontakt:
- Site Public Contact
- E-post: clinicalresearch@sutterhealth.org
-
Huvudutredare:
- Sandra Baril
-
San Diego, California, Förenta staterna, 92123
- Rekrytering
- Rady Children's Hospital - San Diego
-
Kontakt:
- Site Public Contact
- Telefonnummer: 858-966-5934
-
Huvudutredare:
- William D. Roberts
-
San Francisco, California, Förenta staterna, 94158
- Rekrytering
- UCSF Medical Center-Mission Bay
-
Kontakt:
- Site Public Contact
- Telefonnummer: 877-827-3222
- E-post: cancertrials@ucsf.edu
-
Huvudutredare:
- Arun A. Rangaswami
-
-
Colorado
-
Aurora, Colorado, Förenta staterna, 80045
- Rekrytering
- Children's Hospital Colorado
-
Huvudutredare:
- Navin R. Pinto
-
Kontakt:
- Site Public Contact
- Telefonnummer: 303-764-5056
- E-post: josh.b.gordon@nsmtp.kp.org
-
-
Connecticut
-
Hartford, Connecticut, Förenta staterna, 06106
- Rekrytering
- Connecticut Children's Medical Center
-
Kontakt:
- Site Public Contact
- Telefonnummer: 860-545-9981
-
Huvudutredare:
- Michael S. Isakoff
-
New Haven, Connecticut, Förenta staterna, 06520
- Rekrytering
- Yale University
-
Kontakt:
- Site Public Contact
- Telefonnummer: 203-785-5702
- E-post: canceranswers@yale.edu
-
Huvudutredare:
- Farzana Pashankar
-
-
Delaware
-
Wilmington, Delaware, Förenta staterna, 19803
- Rekrytering
- Alfred I duPont Hospital for Children
-
Kontakt:
- Site Public Contact
- Telefonnummer: 302-651-5572
- E-post: Allison.bruce@nemours.org
-
Huvudutredare:
- Sridhi Patel
-
-
District of Columbia
-
Washington D.C., District of Columbia, Förenta staterna, 20010
- Rekrytering
- Children's National Medical Center
-
Huvudutredare:
- Jeffrey S. Dome
-
Kontakt:
- Site Public Contact
- Telefonnummer: 202-476-2800
- E-post: OncCRC_OnCall@childrensnational.org
-
-
Florida
-
Fort Lauderdale, Florida, Förenta staterna, 33316
- Rekrytering
- Broward Health Medical Center
-
Kontakt:
- Site Public Contact
- Telefonnummer: 302-651-5572
- E-post: Allison.bruce@nemours.org
-
Huvudutredare:
- Hector M. Rodriguez-Cortes
-
Fort Myers, Florida, Förenta staterna, 33908
- Rekrytering
- Golisano Children's Hospital of Southwest Florida
-
Kontakt:
- Site Public Contact
- Telefonnummer: 239-343-5333
- E-post: molly.arnstrom@leehealth.org
-
Huvudutredare:
- Emad K. Salman
-
Gainesville, Florida, Förenta staterna, 32610
- Rekrytering
- UF Health Cancer Institute - Gainesville
-
Kontakt:
- Site Public Contact
- Telefonnummer: 352-273-8010
- E-post: cancer-center@ufl.edu
-
Huvudutredare:
- Brian Stover
-
Hollywood, Florida, Förenta staterna, 33021
- Rekrytering
- Memorial Regional Hospital/Joe DiMaggio Children's Hospital
-
Kontakt:
- Site Public Contact
- Telefonnummer: 954-265-1847
- E-post: OHR@mhs.net
-
Huvudutredare:
- Iftikhar Hanif
-
Jacksonville, Florida, Förenta staterna, 32207
- Rekrytering
- Nemours Children's Clinic-Jacksonville
-
Kontakt:
- Site Public Contact
- Telefonnummer: 302-651-5572
- E-post: Allison.bruce@nemours.org
-
Huvudutredare:
- Sridhi Patel
-
Miami, Florida, Förenta staterna, 33155
- Rekrytering
- Nicklaus Children's Hospital
-
Kontakt:
- Site Public Contact
- Telefonnummer: 888-624-2778
-
Huvudutredare:
- Ziad A. Khatib
-
Miami, Florida, Förenta staterna, 33136
- Rekrytering
- University of Miami Miller School of Medicine-Sylvester Cancer Center
-
Kontakt:
- Site Public Contact
- Telefonnummer: 305-243-2647
-
Huvudutredare:
- Meghan McCormick
-
Orlando, Florida, Förenta staterna, 32806
- Rekrytering
- Arnold Palmer Hospital for Children
-
Kontakt:
- Site Public Contact
- Telefonnummer: 321-841-5357
- E-post: Jennifer.spinelli@orlandohealth.com
-
Huvudutredare:
- Zhongbo Hu
-
Orlando, Florida, Förenta staterna, 32827
- Rekrytering
- Nemours Children's Hospital
-
Kontakt:
- Site Public Contact
- Telefonnummer: 302-651-5572
- E-post: Allison.bruce@nemours.org
-
Huvudutredare:
- Sridhi Patel
-
Orlando, Florida, Förenta staterna, 32803
- Rekrytering
- AdventHealth Orlando
-
Kontakt:
- Site Public Contact
- Telefonnummer: 407-303-2090
- E-post: FH.Cancer.Research@flhosp.org
-
Huvudutredare:
- Fouad M. Hajjar
-
St. Petersburg, Florida, Förenta staterna, 33701
- Rekrytering
- Johns Hopkins All Children's Hospital
-
Kontakt:
- Site Public Contact
- Telefonnummer: 727-767-4784
- E-post: Ashley.Repp@jhmi.edu
-
Huvudutredare:
- Jennifer B. Dean
-
West Palm Beach, Florida, Förenta staterna, 33407
- Rekrytering
- Saint Mary's Medical Center
-
Huvudutredare:
- Matthew D. Ramirez
-
Kontakt:
- Site Public Contact
- Telefonnummer: 561-822-4745
-
-
Georgia
-
Atlanta, Georgia, Förenta staterna, 30329
- Rekrytering
- Children's Healthcare of Atlanta - Arthur M Blank Hospital
-
Huvudutredare:
- William T. Cash
-
Kontakt:
- Site Public Contact
- Telefonnummer: 404-785-0232
- E-post: Olivia.Floyd@choa.org
-
Savannah, Georgia, Förenta staterna, 31404
- Rekrytering
- Memorial Health University Medical Center
-
Kontakt:
- Site Public Contact
- Telefonnummer: 912-350-7887
- E-post: Lorraine.OHara@hcahealthcare.com
-
Huvudutredare:
- James N. Yarnall
-
-
Hawaii
-
Honolulu, Hawaii, Förenta staterna, 96826
- Rekrytering
- Kapiolani Medical Center for Women and Children
-
Kontakt:
- Site Public Contact
- Telefonnummer: 808-983-6090
-
Huvudutredare:
- Wade T. Kyono
-
-
Illinois
-
Chicago, Illinois, Förenta staterna, 60611
- Rekrytering
- Lurie Children's Hospital-Chicago
-
Kontakt:
- Site Public Contact
- Telefonnummer: 773-880-4562
-
Huvudutredare:
- Elizabeth A. Sokol
-
Chicago, Illinois, Förenta staterna, 60637
- Rekrytering
- University of Chicago Comprehensive Cancer Center
-
Kontakt:
- Site Public Contact
- Telefonnummer: 773-702-8222
- E-post: cancerclinicaltrials@bsd.uchicago.edu
-
Huvudutredare:
- Ami V. Desai
-
Chicago, Illinois, Förenta staterna, 60612
- Rekrytering
- University of Illinois
-
Kontakt:
- Site Public Contact
- Telefonnummer: 312-355-3046
-
Huvudutredare:
- Dipti S. Dighe
-
Oak Lawn, Illinois, Förenta staterna, 60453
- Rekrytering
- Advocate Children's Hospital-Oak Lawn
-
Kontakt:
- Site Public Contact
- Telefonnummer: 847-723-7570
-
Huvudutredare:
- Rebecca E. McFall
-
Park Ridge, Illinois, Förenta staterna, 60068
- Rekrytering
- Advocate Children's Hospital-Park Ridge
-
Kontakt:
- Site Public Contact
- E-post: helpdesk@childrensoncologygroup.org
-
Huvudutredare:
- Rebecca E. McFall
-
Peoria, Illinois, Förenta staterna, 61637
- Rekrytering
- OSF Children's Hospital of Illinois
-
Huvudutredare:
- Prerna Kumar
-
Kontakt:
- Site Public Contact
- Telefonnummer: 309-624-4945
- E-post: ChildrensHospitalofIllinois@osfhealthcare.org
-
Springfield, Illinois, Förenta staterna, 62702
- Rekrytering
- Southern Illinois University School of Medicine
-
Kontakt:
- Site Public Contact
- Telefonnummer: 217-545-7929
-
Huvudutredare:
- Gregory P. Brandt
-
-
Indiana
-
Indianapolis, Indiana, Förenta staterna, 46202
- Rekrytering
- Riley Hospital for Children
-
Kontakt:
- Site Public Contact
- Telefonnummer: 800-248-1199
-
Huvudutredare:
- Marissa Just
-
Indianapolis, Indiana, Förenta staterna, 46260
- Rekrytering
- Ascension Saint Vincent Indianapolis Hospital
-
Kontakt:
- Site Public Contact
- Telefonnummer: 317-338-2194
- E-post: research@stvincent.org
-
Huvudutredare:
- Bassem I. Razzouk
-
-
Iowa
-
Des Moines, Iowa, Förenta staterna, 50309
- Rekrytering
- Blank Children's Hospital
-
Kontakt:
- Site Public Contact
- Telefonnummer: 515-241-8912
- E-post: samantha.mallory@unitypoint.org
-
Huvudutredare:
- Samantha L. Mallory
-
Iowa City, Iowa, Förenta staterna, 52242
- Rekrytering
- University of Iowa/Holden Comprehensive Cancer Center
-
Kontakt:
- Site Public Contact
- Telefonnummer: 800-237-1225
-
Huvudutredare:
- Andrew P. Groves
-
-
Kansas
-
Wichita, Kansas, Förenta staterna, 67214
- Rekrytering
- Wesley Medical Center
-
Kontakt:
- Site Public Contact
- Telefonnummer: 316-962-7802
- E-post: WesleyResearch@wesleymc.com
-
Huvudutredare:
- Nathan S. Hall
-
-
Kentucky
-
Lexington, Kentucky, Förenta staterna, 40536
- Rekrytering
- University of Kentucky/Markey Cancer Center
-
Kontakt:
- Site Public Contact
- Telefonnummer: 859-257-3379
-
Huvudutredare:
- James T. Badgett
-
Louisville, Kentucky, Förenta staterna, 40202
- Rekrytering
- Norton Children's Hospital
-
Kontakt:
- Site Public Contact
- Telefonnummer: 502-629-5500
- E-post: CancerResource@nortonhealthcare.org
-
Huvudutredare:
- Michael J. Ferguson
-
-
Louisiana
-
New Orleans, Louisiana, Förenta staterna, 70118
- Rekrytering
- Children's Hospital New Orleans
-
Huvudutredare:
- Maria C. Velez-Yanguas
-
Kontakt:
- Site Public Contact
- Telefonnummer: 504-894-5377
-
-
Maine
-
Bangor, Maine, Förenta staterna, 04401
- Rekrytering
- Eastern Maine Medical Center
-
Kontakt:
- Site Public Contact
- Telefonnummer: 207-973-4274
-
Huvudutredare:
- Daniel L. Callaway
-
Scarborough, Maine, Förenta staterna, 04074
- Rekrytering
- Maine Children's Cancer Program
-
Huvudutredare:
- Sei-Gyung K. Sze
-
Kontakt:
- Site Public Contact
- Telefonnummer: 207-396-8670
- E-post: clinicalresearch@mainehealth.org
-
-
Maryland
-
Baltimore, Maryland, Förenta staterna, 21287
- Rekrytering
- Johns Hopkins University/Sidney Kimmel Cancer Center
-
Huvudutredare:
- Allen R. Chen
-
Kontakt:
- Site Public Contact
- Telefonnummer: 410-955-8804
- E-post: jhcccro@jhmi.edu
-
Baltimore, Maryland, Förenta staterna, 21215
- Rekrytering
- Sinai Hospital of Baltimore
-
Huvudutredare:
- Jason M. Fixler
-
Kontakt:
- Site Public Contact
- Telefonnummer: 410-601-9083
-
Baltimore, Maryland, Förenta staterna, 21201
- Rekrytering
- University of Maryland/Greenebaum Cancer Center
-
Kontakt:
- Site Public Contact
- Telefonnummer: 800-888-8823
-
Huvudutredare:
- Teresa A. York
-
Bethesda, Maryland, Förenta staterna, 20889-5600
- Rekrytering
- Walter Reed National Military Medical Center
-
Kontakt:
- Site Public Contact
- Telefonnummer: 301-319-2100
-
Huvudutredare:
- Kip R. Hartman
-
-
Massachusetts
-
Boston, Massachusetts, Förenta staterna, 02114
- Rekrytering
- Massachusetts General Hospital Cancer Center
-
Kontakt:
- Site Public Contact
- Telefonnummer: 877-726-5130
-
Huvudutredare:
- Lauren H. Boal
-
Boston, Massachusetts, Förenta staterna, 02215
- Rekrytering
- Dana-Farber Cancer Institute
-
Kontakt:
- Site Public Contact
- Telefonnummer: 877-442-3324
-
Huvudutredare:
- Suzanne Shusterman
-
-
Michigan
-
Ann Arbor, Michigan, Förenta staterna, 48109
- Rekrytering
- C S Mott Children's Hospital
-
Kontakt:
- Site Public Contact
- Telefonnummer: 800-865-1125
-
Huvudutredare:
- Rajen Mody
-
Detroit, Michigan, Förenta staterna, 48201
- Upphängd
- Children's Hospital of Michigan
-
Grand Rapids, Michigan, Förenta staterna, 49503
- Rekrytering
- Corewell Health Grand Rapids Hospitals - Helen DeVos Children's Hospital
-
Kontakt:
- Site Public Contact
- Telefonnummer: 616-391-1230
- E-post: crcwm-regulatory@crcwm.org
-
Huvudutredare:
- Kathleen Y. Butler
-
Kalamazoo, Michigan, Förenta staterna, 49007
- Rekrytering
- Bronson Methodist Hospital
-
Kontakt:
- Site Public Contact
- Telefonnummer: 616-391-1230
- E-post: crcwm-regulatory@crcwm.org
-
Huvudutredare:
- Kathleen Y. Butler
-
Royal Oak, Michigan, Förenta staterna, 48073
- Rekrytering
- Corewell Health Children's
-
Kontakt:
- Site Public Contact
- Telefonnummer: 248-551-7695
-
Huvudutredare:
- Marie V. Nelson
-
-
Minnesota
-
Minneapolis, Minnesota, Förenta staterna, 55404
- Rekrytering
- Children's Hospitals and Clinics of Minnesota - Minneapolis
-
Huvudutredare:
- Michael K. Richards
-
Kontakt:
- Site Public Contact
- Telefonnummer: 612-813-5913
- E-post: pauline.mitby@childrensmn.org
-
Minneapolis, Minnesota, Förenta staterna, 55455
- Rekrytering
- University of Minnesota/Masonic Cancer Center
-
Kontakt:
- Site Public Contact
- Telefonnummer: 612-624-2620
-
Huvudutredare:
- Robin L. Williams
-
Rochester, Minnesota, Förenta staterna, 55905
- Rekrytering
- Mayo Clinic in Rochester
-
Kontakt:
- Site Public Contact
- Telefonnummer: 855-776-0015
-
Huvudutredare:
- Peter Schoettler
-
-
Mississippi
-
Jackson, Mississippi, Förenta staterna, 39216
- Rekrytering
- University of Mississippi Medical Center
-
Kontakt:
- Site Public Contact
- Telefonnummer: 601-815-6700
-
Huvudutredare:
- Amanda Strobel
-
-
Missouri
-
Columbia, Missouri, Förenta staterna, 65212
- Rekrytering
- University of Missouri Children's Hospital
-
Huvudutredare:
- Barbara A. Gruner
-
Kontakt:
- Site Public Contact
- Telefonnummer: 573-882-1960
- E-post: snwq62@health.missouri.edu
-
Kansas City, Missouri, Förenta staterna, 64108
- Rekrytering
- Children's Mercy Hospitals and Clinics
-
Huvudutredare:
- Keith J. August
-
Kontakt:
- Site Public Contact
- Telefonnummer: 816-302-6808
- E-post: COGResearchGroup@cmh.edu
-
St Louis, Missouri, Förenta staterna, 63110
- Rekrytering
- Washington University School of Medicine
-
Kontakt:
- Site Public Contact
- Telefonnummer: 800-600-3606
- E-post: info@siteman.wustl.edu
-
Huvudutredare:
- Frederick S. Huang
-
St Louis, Missouri, Förenta staterna, 63141
- Rekrytering
- Mercy Hospital Saint Louis
-
Kontakt:
- Site Public Contact
- Telefonnummer: 314-251-7066
-
Huvudutredare:
- Robin D. Hanson
-
-
Nebraska
-
Omaha, Nebraska, Förenta staterna, 68114
- Rekrytering
- Children's Hospital and Medical Center of Omaha
-
Kontakt:
- Site Public Contact
- Telefonnummer: 402-955-3949
-
Huvudutredare:
- Jill C. Beck
-
Omaha, Nebraska, Förenta staterna, 68198
- Rekrytering
- University of Nebraska Medical Center
-
Kontakt:
- Site Public Contact
- Telefonnummer: 402-559-6941
- E-post: unmcrsa@unmc.edu
-
Huvudutredare:
- Jill C. Beck
-
-
Nevada
-
Las Vegas, Nevada, Förenta staterna, 89135
- Rekrytering
- Alliance for Childhood Diseases/Cure 4 the Kids Foundation
-
Kontakt:
- Site Public Contact
- Telefonnummer: 702-384-0013
- E-post: research@sncrf.org
-
Huvudutredare:
- Joseph L. Lasky
-
-
New Hampshire
-
Lebanon, New Hampshire, Förenta staterna, 03756
- Rekrytering
- Dartmouth Hitchcock Medical Center/Dartmouth Cancer Center
-
Huvudutredare:
- Angela Ricci
-
Kontakt:
- Site Public Contact
- Telefonnummer: 800-639-6918
- E-post: cancer.research.nurse@dartmouth.edu
-
-
New Jersey
-
Hackensack, New Jersey, Förenta staterna, 07601
- Rekrytering
- Hackensack University Medical Center
-
Huvudutredare:
- Katharine Offer
-
Kontakt:
- Site Public Contact
- Telefonnummer: 551-996-2897
-
Morristown, New Jersey, Förenta staterna, 07960
- Rekrytering
- Morristown Medical Center
-
Kontakt:
- Site Public Contact
- Telefonnummer: 973-971-5900
-
Huvudutredare:
- Kathryn L. Laurie
-
New Brunswick, New Jersey, Förenta staterna, 08901
- Rekrytering
- Saint Peter's University Hospital
-
Huvudutredare:
- Nibal A. Zaghloul
-
Kontakt:
- Site Public Contact
- Telefonnummer: 732-745-8600
- E-post: officeofresearch@saintpetersuh.com
-
New Brunswick, New Jersey, Förenta staterna, 08903
- Rekrytering
- Rutgers Cancer Institute of New Jersey-Robert Wood Johnson University Hospital
-
Kontakt:
- Site Public Contact
- Telefonnummer: 732-235-8675
-
Huvudutredare:
- Nehal S. Parikh
-
Newark, New Jersey, Förenta staterna, 07112
- Rekrytering
- Newark Beth Israel Medical Center
-
Kontakt:
- Site Public Contact
- Telefonnummer: 973-926-7230
- E-post: Christine.Kosmides@rwjbh.org
-
Huvudutredare:
- Teena Bhatla
-
Paterson, New Jersey, Förenta staterna, 07503
- Rekrytering
- Saint Joseph's Regional Medical Center
-
Kontakt:
- Site Public Contact
- Telefonnummer: 973-754-2207
- E-post: HallL@sjhmc.org
-
Huvudutredare:
- Alissa Kahn
-
-
New Mexico
-
Albuquerque, New Mexico, Förenta staterna, 87106
- Upphängd
- University of New Mexico Cancer Center
-
-
New York
-
Albany, New York, Förenta staterna, 12208
- Rekrytering
- Albany Medical Center
-
Kontakt:
- Site Public Contact
- Telefonnummer: 518-262-5513
-
Huvudutredare:
- Lauren R. Weintraub
-
Buffalo, New York, Förenta staterna, 14263
- Rekrytering
- Roswell Park Cancer Institute
-
Kontakt:
- Site Public Contact
- Telefonnummer: 800-767-9355
- E-post: askroswell@roswellpark.org
-
Huvudutredare:
- Clare J. Twist
-
Mineola, New York, Förenta staterna, 11501
- Rekrytering
- NYU Langone Hospital - Long Island
-
Kontakt:
- Site Public Contact
- Telefonnummer: 212-263-4432
- E-post: cancertrials@nyulangone.org
-
Huvudutredare:
- Chana L. Glasser
-
New Hyde Park, New York, Förenta staterna, 11040
- Rekrytering
- The Steven and Alexandra Cohen Children's Medical Center of New York
-
Kontakt:
- Site Public Contact
- Telefonnummer: 718-470-3460
-
Huvudutredare:
- Julie I. Krystal
-
New York, New York, Förenta staterna, 10032
- Rekrytering
- NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center
-
Huvudutredare:
- Nobuko Hijiya
-
Kontakt:
- Site Public Contact
- Telefonnummer: 212-342-5162
- E-post: cancerclinicaltrials@cumc.columbia.edu
-
New York, New York, Förenta staterna, 10016
- Rekrytering
- Laura and Isaac Perlmutter Cancer Center at NYU Langone
-
Huvudutredare:
- Elizabeth A. Raetz
-
Kontakt:
- Site Public Contact
- E-post: CancerTrials@nyulangone.org
-
Rochester, New York, Förenta staterna, 14642
- Rekrytering
- University of Rochester
-
Kontakt:
- Site Public Contact
- Telefonnummer: 585-275-5830
-
Huvudutredare:
- Rafi R. Kazi
-
Syracuse, New York, Förenta staterna, 13210
- Rekrytering
- State University of New York Upstate Medical University
-
Kontakt:
- Site Public Contact
- Telefonnummer: 315-464-5476
-
Huvudutredare:
- Melanie A. Comito
-
The Bronx, New York, Förenta staterna, 10467
- Rekrytering
- Montefiore Medical Center - Moses Campus
-
Kontakt:
- Site Public Contact
- Telefonnummer: 718-379-6866
- E-post: eskwak@montefiore.org
-
Huvudutredare:
- Alice Lee
-
Valhalla, New York, Förenta staterna, 10595
- Rekrytering
- New York Medical College
-
Kontakt:
- Site Public Contact
- Telefonnummer: 914-594-3794
-
Huvudutredare:
- Andrew J. Bellantoni
-
-
North Carolina
-
Asheville, North Carolina, Förenta staterna, 28801
- Rekrytering
- Mission Hospital
-
Kontakt:
- Site Public Contact
- Telefonnummer: 828-213-7055
- E-post: NCDV.ResearchRegulatory@HCAHealthcare.com
-
Huvudutredare:
- Douglas J. Scothorn
-
Chapel Hill, North Carolina, Förenta staterna, 27599
- Rekrytering
- UNC Lineberger Comprehensive Cancer Center
-
Kontakt:
- Site Public Contact
- Telefonnummer: 877-668-0683
- E-post: cancerclinicaltrials@med.unc.edu
-
Huvudutredare:
- Thomas B. Alexander
-
Charlotte, North Carolina, Förenta staterna, 28203
- Rekrytering
- Carolinas Medical Center/Levine Cancer Institute
-
Kontakt:
- Site Public Contact
- Telefonnummer: 800-804-9376
-
Huvudutredare:
- Joel A. Kaplan
-
Charlotte, North Carolina, Förenta staterna, 28204
- Rekrytering
- Novant Health Presbyterian Medical Center
-
Kontakt:
- Site Public Contact
- Telefonnummer: 980-201-6360
- E-post: kashah@novanthealth.org
-
Huvudutredare:
- Holly Edington
-
Durham, North Carolina, Förenta staterna, 27710
- Rekrytering
- Duke University Medical Center
-
Huvudutredare:
- Jessica M. Sun
-
Kontakt:
- Site Public Contact
- Telefonnummer: 888-275-3853
-
Greenville, North Carolina, Förenta staterna, 27834
- Rekrytering
- East Carolina University
-
Kontakt:
- Site Public Contact
- Telefonnummer: 252-744-1015
- E-post: eubankss@ecu.edu
-
Huvudutredare:
- Andrea R. Whitfield
-
Winston-Salem, North Carolina, Förenta staterna, 27157
- Rekrytering
- Wake Forest University Health Sciences
-
Kontakt:
- Site Public Contact
- Telefonnummer: 336-713-6771
-
Huvudutredare:
- Sarah Supples
-
-
North Dakota
-
Fargo, North Dakota, Förenta staterna, 58122
- Rekrytering
- Sanford Broadway Medical Center
-
Kontakt:
- Site Public Contact
- Telefonnummer: 701-323-5760
- E-post: OncologyClinicalTrialsFargo@sanfordhealth.org
-
Huvudutredare:
- Samuel J. Milanovich
-
-
Ohio
-
Akron, Ohio, Förenta staterna, 44308
- Rekrytering
- Children's Hospital Medical Center of Akron
-
Kontakt:
- Site Public Contact
- Telefonnummer: 330-543-3193
-
Huvudutredare:
- Lauren R. Draper
-
Cincinnati, Ohio, Förenta staterna, 45229
- Rekrytering
- Cincinnati Children's Hospital Medical Center
-
Kontakt:
- Site Public Contact
- Telefonnummer: 513-636-2799
- E-post: cancer@cchmc.org
-
Huvudutredare:
- Katherine M. Somers
-
Cleveland, Ohio, Förenta staterna, 44195
- Rekrytering
- Cleveland Clinic Foundation
-
Kontakt:
- Site Public Contact
- Telefonnummer: 866-223-8100
- E-post: TaussigResearch@ccf.org
-
Huvudutredare:
- Matteo M. Trucco
-
Cleveland, Ohio, Förenta staterna, 44106
- Rekrytering
- Rainbow Babies and Childrens Hospital
-
Kontakt:
- Site Public Contact
- Telefonnummer: 216-844-5437
-
Huvudutredare:
- Duncan S. Stearns
-
Columbus, Ohio, Förenta staterna, 43205
- Rekrytering
- Nationwide Children's Hospital
-
Kontakt:
- Site Public Contact
- Telefonnummer: 614-722-6039
- E-post: Melinda.Triplet@nationwidechildrens.org
-
Huvudutredare:
- Mark A. Ranalli
-
Dayton, Ohio, Förenta staterna, 45404
- Rekrytering
- Dayton Children's Hospital
-
Kontakt:
- Site Public Contact
- Telefonnummer: 800-228-4055
-
Huvudutredare:
- Jordan M. Wright
-
Toledo, Ohio, Förenta staterna, 43606
- Rekrytering
- ProMedica Toledo Hospital/Russell J Ebeid Children's Hospital
-
Kontakt:
- Site Public Contact
- Telefonnummer: 419-824-1842
- E-post: PCIOncResearch@promedica.org
-
Huvudutredare:
- Jamie L. Dargart
-
-
Oklahoma
-
Oklahoma City, Oklahoma, Förenta staterna, 73104
- Rekrytering
- University of Oklahoma Health Sciences Center
-
Kontakt:
- Site Public Contact
- Telefonnummer: 405-271-8777
- E-post: ou-clinical-trials@ouhsc.edu
-
Huvudutredare:
- Rene Y. McNall-Knapp
-
Tulsa, Oklahoma, Förenta staterna, 74136
- Rekrytering
- Saint Francis Children's Hospital
-
Huvudutredare:
- Jill A. Salo
-
Kontakt:
- Site Public Contact
- Telefonnummer: 918-502-6720
-
-
Oregon
-
Portland, Oregon, Förenta staterna, 97227
- Rekrytering
- Legacy Emanuel Children's Hospital
-
Kontakt:
- Site Public Contact
- Telefonnummer: 503-413-2560
-
Huvudutredare:
- Jason M. Glover
-
Portland, Oregon, Förenta staterna, 97239
- Rekrytering
- Oregon Health and Science University
-
Kontakt:
- Site Public Contact
- Telefonnummer: 503-494-1080
- E-post: trials@ohsu.edu
-
Huvudutredare:
- Susan J. Lindemulder
-
-
Pennsylvania
-
Allentown, Pennsylvania, Förenta staterna, 18103
- Rekrytering
- Lehigh Valley Hospital-Cedar Crest
-
Kontakt:
- Site Public Contact
- Telefonnummer: 610-402-9543
- E-post: Morgan_M.Horton@lvhn.org
-
Huvudutredare:
- Jacob A. Troutman
-
Danville, Pennsylvania, Förenta staterna, 17822
- Rekrytering
- Geisinger Medical Center
-
Huvudutredare:
- Jagadeesh Ramdas
-
Kontakt:
- Site Public Contact
- Telefonnummer: 570-271-5251
- E-post: cancerresearch@geisinger.edu
-
Philadelphia, Pennsylvania, Förenta staterna, 19104
- Rekrytering
- Children's Hospital of Philadelphia
-
Huvudutredare:
- Rochelle Bagatell
-
Kontakt:
- Site Public Contact
- Telefonnummer: 267-425-5544
- E-post: CancerTrials@email.chop.edu
-
Philadelphia, Pennsylvania, Förenta staterna, 19134
- Rekrytering
- Saint Christopher's Hospital for Children
-
Kontakt:
- Site Public Contact
- Telefonnummer: 215-427-8991
-
Huvudutredare:
- Gregory E. Halligan
-
Pittsburgh, Pennsylvania, Förenta staterna, 15224
- Rekrytering
- Children's Hospital of Pittsburgh of UPMC
-
Kontakt:
- Site Public Contact
- Telefonnummer: 412-692-8570
- E-post: jean.tersak@chp.edu
-
Huvudutredare:
- Jean M. Tersak
-
-
Rhode Island
-
Providence, Rhode Island, Förenta staterna, 02903
- Rekrytering
- Rhode Island Hospital
-
Huvudutredare:
- Bradley DeNardo
-
Kontakt:
- Site Public Contact
- Telefonnummer: 401-444-1488
-
-
South Carolina
-
Charleston, South Carolina, Förenta staterna, 29425
- Rekrytering
- Medical University of South Carolina
-
Kontakt:
- Site Public Contact
- Telefonnummer: 843-792-9321
- E-post: hcc-clinical-trials@musc.edu
-
Huvudutredare:
- Jacqueline M. Kraveka
-
Columbia, South Carolina, Förenta staterna, 29203
- Rekrytering
- Prisma Health Richland Hospital
-
Huvudutredare:
- Stuart L. Cramer
-
Kontakt:
- Site Public Contact
- Telefonnummer: 864-522-4317
- E-post: Kim.Williams3@prismahealth.org
-
Greenville, South Carolina, Förenta staterna, 29605
- Rekrytering
- BI-LO Charities Children's Cancer Center
-
Huvudutredare:
- Aniket Saha
-
Kontakt:
- Site Public Contact
- Telefonnummer: 864-522-4317
- E-post: Kim.Williams3@prismahealth.org
-
-
South Dakota
-
Sioux Falls, South Dakota, Förenta staterna, 57117-5134
- Rekrytering
- Sanford USD Medical Center - Sioux Falls
-
Kontakt:
- Site Public Contact
- Telefonnummer: 605-312-3320
- E-post: OncologyClinicalTrialsSF@SanfordHealth.org
-
Huvudutredare:
- Jordan Fritch-Hanson
-
-
Tennessee
-
Knoxville, Tennessee, Förenta staterna, 37916
- Rekrytering
- East Tennessee Childrens Hospital
-
Kontakt:
- Site Public Contact
- Telefonnummer: 865-541-8266
-
Huvudutredare:
- Susan E. Spiller
-
Memphis, Tennessee, Förenta staterna, 38105
- Rekrytering
- Saint Jude Children's Research Hospital
-
Huvudutredare:
- Sara M. Federico
-
Kontakt:
- Site Public Contact
- Telefonnummer: 888-226-4343
- E-post: referralinfo@stjude.org
-
Nashville, Tennessee, Förenta staterna, 37232
- Rekrytering
- Vanderbilt University/Ingram Cancer Center
-
Huvudutredare:
- Daniel J. Benedetti
-
Kontakt:
- Site Public Contact
- Telefonnummer: 800-811-8480
-
Nashville, Tennessee, Förenta staterna, 37203
- Rekrytering
- The Children's Hospital at TriStar Centennial
-
Kontakt:
- Site Public Contact
- Telefonnummer: 615-342-1919
-
Huvudutredare:
- Clinton M. Carroll
-
-
Texas
-
Austin, Texas, Förenta staterna, 78723
- Rekrytering
- Dell Children's Medical Center of Central Texas
-
Kontakt:
- Site Public Contact
- Telefonnummer: 512-628-1902
- E-post: TXAUS-DL-SFCHemonc.research@ascension.org
-
Huvudutredare:
- Shannon M. Cohn
-
Corpus Christi, Texas, Förenta staterna, 78411
- Rekrytering
- Driscoll Children's Hospital
-
Kontakt:
- Site Public Contact
- Telefonnummer: 361-694-5311
- E-post: Crystal.DeLosSantos@dchstx.org
-
Huvudutredare:
- Nkechi I. Mba
-
Dallas, Texas, Förenta staterna, 75390
- Rekrytering
- UT Southwestern/Simmons Cancer Center-Dallas
-
Huvudutredare:
- Tanya C. Watt
-
Kontakt:
- Site Public Contact
- Telefonnummer: 214-648-7097
- E-post: canceranswerline@UTSouthwestern.edu
-
Dallas, Texas, Förenta staterna, 75230
- Rekrytering
- Medical City Dallas Hospital
-
Kontakt:
- Site Public Contact
- Telefonnummer: 972-566-5588
-
Huvudutredare:
- Maurizio L. Ghisoli
-
El Paso, Texas, Förenta staterna, 79905
- Rekrytering
- El Paso Children's Hospital
-
Kontakt:
- Site Public Contact
- Telefonnummer: 915-298-5444
- E-post: ranjan.bista@ttuhsc.edu
-
Huvudutredare:
- Benjamin Carcamo
-
Fort Worth, Texas, Förenta staterna, 76104
- Rekrytering
- Cook Children's Medical Center
-
Kontakt:
- Site Public Contact
- Telefonnummer: 682-885-2103
- E-post: CookChildrensResearch@cookchildrens.org
-
Huvudutredare:
- Chelsee Greer
-
Houston, Texas, Förenta staterna, 77030
- Rekrytering
- Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center
-
Kontakt:
- Site Public Contact
- Telefonnummer: 713-798-1354
- E-post: burton@bcm.edu
-
Huvudutredare:
- Jennifer H. Foster
-
Houston, Texas, Förenta staterna, 77030
- Rekrytering
- UT MD Anderson Cancer Center
-
Kontakt:
- Site Public Contact
- Telefonnummer: 866-632-6789
- E-post: askmdanderson@mdanderson.org
-
Huvudutredare:
- Najat C. Daw
-
Lubbock, Texas, Förenta staterna, 79410
- Rekrytering
- Covenant Children's Hospital
-
Huvudutredare:
- Kishor M. Bhende
-
Kontakt:
- Site Public Contact
- Telefonnummer: 806-725-8657
- E-post: mbisbee@providence.org
-
Lubbock, Texas, Förenta staterna, 79415
- Rekrytering
- UMC Cancer Center / UMC Health System
-
Kontakt:
- Site Public Contact
- Telefonnummer: 806-775-8590
-
Huvudutredare:
- Erin K. Barr
-
San Antonio, Texas, Förenta staterna, 78207
- Rekrytering
- Children's Hospital of San Antonio
-
Kontakt:
- Site Public Contact
- Telefonnummer: 210-704-2894
- E-post: bridget.medina@christushealth.org
-
Huvudutredare:
- Julie Voeller
-
San Antonio, Texas, Förenta staterna, 78229
- Rekrytering
- University of Texas Health Science Center at San Antonio
-
Kontakt:
- Site Public Contact
- Telefonnummer: 210-450-3800
- E-post: phoresearchoffice@uthscsa.edu
-
Huvudutredare:
- Aaron J. Sugalski
-
San Antonio, Texas, Förenta staterna, 78229
- Rekrytering
- Methodist Children's Hospital of South Texas
-
Kontakt:
- Site Public Contact
- Telefonnummer: 210-575-6240
- E-post: Vinod.GidvaniDiaz@hcahealthcare.com
-
Huvudutredare:
- Jose M. Esquilin
-
-
Utah
-
Salt Lake City, Utah, Förenta staterna, 84113
- Rekrytering
- Primary Children's Hospital
-
Kontakt:
- Site Public Contact
- Telefonnummer: 801-585-5270
-
Huvudutredare:
- Leonora R. Slatnick
-
-
Vermont
-
Burlington, Vermont, Förenta staterna, 05405
- Rekrytering
- University of Vermont and State Agricultural College
-
Kontakt:
- Site Public Contact
- Telefonnummer: 802-656-8990
- E-post: rpo@uvm.edu
-
Huvudutredare:
- Jessica L. Heath
-
-
Virginia
-
Charlottesville, Virginia, Förenta staterna, 22908
- Rekrytering
- University of Virginia Cancer Center
-
Kontakt:
- Site Public Contact
- Telefonnummer: 434-243-6303
- E-post: uvacancertrials@hscmail.mcc.virginia.edu
-
Huvudutredare:
- Brian C. Belyea
-
Portsmouth, Virginia, Förenta staterna, 23708-2197
- Rekrytering
- Naval Medical Center - Portsmouth
-
Kontakt:
- Site Public Contact
- Telefonnummer: 757-953-5939
-
Huvudutredare:
- Karin Brockman
-
-
Washington
-
Seattle, Washington, Förenta staterna, 98105
- Rekrytering
- Seattle Children's Hospital
-
Kontakt:
- Site Public Contact
- Telefonnummer: 866-987-2000
-
Huvudutredare:
- Sarah E. Leary
-
Spokane, Washington, Förenta staterna, 99204
- Rekrytering
- Providence Sacred Heart Medical Center and Children's Hospital
-
Kontakt:
- Site Public Contact
- Telefonnummer: 800-228-6618
- E-post: HopeBeginsHere@providence.org
-
Huvudutredare:
- Judy L. Felgenhauer
-
Tacoma, Washington, Förenta staterna, 98405
- Rekrytering
- Mary Bridge Children's Hospital and Health Center
-
Kontakt:
- Site Public Contact
- Telefonnummer: 253-403-1461
- E-post: research@multicare.org
-
Huvudutredare:
- Robert G. Irwin
-
-
West Virginia
-
Huntington, West Virginia, Förenta staterna, 25701
- Rekrytering
- Edwards Comprehensive Cancer Center
-
Huvudutredare:
- Mark A. Ranalli
-
Kontakt:
- Site Public Contact
- Telefonnummer: 304-399-6566
- E-post: Christina.Cole@chhi.org
-
Morgantown, West Virginia, Förenta staterna, 26506
- Rekrytering
- West Virginia University Healthcare
-
Kontakt:
- Site Public Contact
- Telefonnummer: 304-293-7374
- E-post: cancertrialsinfo@hsc.wvu.edu
-
Huvudutredare:
- Ashley E. Meyer
-
-
Wisconsin
-
Green Bay, Wisconsin, Förenta staterna, 54301
- Upphängd
- Saint Vincent Hospital Cancer Center Green Bay
-
Madison, Wisconsin, Förenta staterna, 53792
- Rekrytering
- University of Wisconsin Carbone Cancer Center - University Hospital
-
Kontakt:
- Site Public Contact
- Telefonnummer: 800-622-8922
- E-post: clinicaltrials@cancer.wisc.edu
-
Huvudutredare:
- Margo L. Hoover-Regan
-
Marshfield, Wisconsin, Förenta staterna, 54449
- Rekrytering
- Marshfield Medical Center-Marshfield
-
Kontakt:
- Site Public Contact
- Telefonnummer: 800-782-8581
- E-post: oncology.clinical.trials@marshfieldresearch.org
-
Huvudutredare:
- Michelle A. Manalang
-
Milwaukee, Wisconsin, Förenta staterna, 53226
- Rekrytering
- Children's Hospital of Wisconsin
-
Huvudutredare:
- Angela Steineck
-
Kontakt:
- Site Public Contact
- Telefonnummer: 414-955-4727
- E-post: MACCCTO@mcw.edu
-
-
-
-
-
Québec, Kanada, G1V 4G2
- Rekrytering
- CHU de Quebec-Centre Hospitalier de l'Universite Laval (CHUL)
-
Huvudutredare:
- Bruno Michon
-
Kontakt:
- Site Public Contact
- Telefonnummer: 418-525-4444
- E-post: rechclinique@crchudequebec.ulaval.ca
-
-
Alberta
-
Calgary, Alberta, Kanada, T3B 6A8
- Rekrytering
- Alberta Children's Hospital
-
Kontakt:
- Site Public Contact
- Telefonnummer: 403-220-6898
- E-post: research4kids@ucalgary.ca
-
Huvudutredare:
- Victor A. Lewis
-
Edmonton, Alberta, Kanada, T6G 2B7
- Rekrytering
- University of Alberta Hospital
-
Kontakt:
- Site Public Contact
- Telefonnummer: 780-407-8798
- E-post: pedsoncologyresearch@ahs.ca
-
Huvudutredare:
- Sarah J. McKillop
-
-
British Columbia
-
Vancouver, British Columbia, Kanada, V6H 3V4
- Rekrytering
- British Columbia Children's Hospital
-
Kontakt:
- Site Public Contact
- Telefonnummer: 6477 604-875-2345
-
Huvudutredare:
- Rebecca J. Deyell
-
-
Manitoba
-
Winnipeg, Manitoba, Kanada, R3E 0V9
- Rekrytering
- CancerCare Manitoba
-
Kontakt:
- Site Public Contact
- Telefonnummer: 866-561-1026
- E-post: ctu_web@cancercare.mb.ca
-
Huvudutredare:
- Stephanie M. Villeneuve
-
-
Newfoundland and Labrador
-
St. John's, Newfoundland and Labrador, Kanada, A1B 3V6
- Rekrytering
- Janeway Child Health Centre
-
Huvudutredare:
- Lisa A. Goodyear
-
Kontakt:
- Site Public Contact
- Telefonnummer: 709-777-8727
- E-post: beverlyj.mitchell@easternhealth.ca
-
-
Nova Scotia
-
Halifax, Nova Scotia, Kanada, B3K 6R8
- Rekrytering
- IWK Health Centre
-
Kontakt:
- Site Public Contact
- Telefonnummer: 902-470-8520
- E-post: Research@iwk.nshealth.ca
-
Huvudutredare:
- Chelsea Ash
-
-
Ontario
-
Hamilton, Ontario, Kanada, L8N 3Z5
- Rekrytering
- McMaster Children's Hospital at Hamilton Health Sciences
-
Kontakt:
- Site Public Contact
- Telefonnummer: 905-521-2100
-
Huvudutredare:
- Uma H. Athale
-
London, Ontario, Kanada, N6A 5W9
- Rekrytering
- Children's Hospital
-
Kontakt:
- Site Public Contact
- Telefonnummer: 519-685-8306
-
Huvudutredare:
- Shayna M. Zelcer
-
Ottawa, Ontario, Kanada, K1H 8L1
- Rekrytering
- Children's Hospital of Eastern Ontario
-
Kontakt:
- Site Public Contact
- Telefonnummer: 613-737-7600
-
Huvudutredare:
- Donna L. Johnston
-
Toronto, Ontario, Kanada, M5G 1X8
- Rekrytering
- Hospital for Sick Children
-
Kontakt:
- Site Public Contact
- Telefonnummer: 416-813-7654
- E-post: ask.CRS@sickkids.ca
-
Huvudutredare:
- Daniel A. Morgenstern
-
-
Quebec
-
Montreal, Quebec, Kanada, H3H 1P3
- Rekrytering
- The Montreal Children's Hospital of the MUHC
-
Kontakt:
- Site Public Contact
- Telefonnummer: 514-412-4445
- E-post: info@thechildren.com
-
Huvudutredare:
- Stephanie Mourad
-
Montreal, Quebec, Kanada, H3T 1C5
- Rekrytering
- Centre Hospitalier Universitaire Sainte-Justine
-
Huvudutredare:
- Monia Marzouki
-
Kontakt:
- Site Public Contact
- Telefonnummer: 514-345-4931
- E-post: yvan.samson@umontreal.ca
-
Sherbrooke, Quebec, Kanada, J1H 5N4
- Rekrytering
- Centre Hospitalier Universitaire de Sherbrooke-Fleurimont
-
Kontakt:
- Site Public Contact
- Telefonnummer: 819-820-6480
- E-post: crcinformation.chus@ssss.gouv.qc.ca
-
Huvudutredare:
- Stephanie Vairy
-
-
Saskatchewan
-
Saskatoon, Saskatchewan, Kanada, S7N 0W8
- Rekrytering
- Jim Pattison Children's Hospital
-
Huvudutredare:
- Kathleen Felton
-
Kontakt:
- Site Public Contact
- Telefonnummer: 306-655-3544
- E-post: Jessica.Marien@saskhealthauthority.ca
-
-
-
-
Auckland
-
Grafton, Auckland, Nya Zeeland, 1145
- Rekrytering
- Starship Children's Hospital
-
Huvudutredare:
- Andrew C. Wood
-
Kontakt:
- Site Public Contact
- Telefonnummer: 0800 728 436
-
-
-
-
-
San Juan, Puerto Rico, 00926
- Rekrytering
- University Pediatric Hospital
-
Kontakt:
- Site Public Contact
- Telefonnummer: 787-474-0333
-
Huvudutredare:
- Maria E. Echevarria
-
-
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
Tar emot friska volontärer
Kön som är behöriga för studier
Beskrivning
Inclusion Criteria:
-
Patients must be enrolled on APEC14B1 and have consented to testing through the Molecular Characterization Initiative (MCI), prior to enrollment on ANBL2131
-
≤ 30 years at the time of initial diagnosis with high-risk disease
-
* Must have a diagnosis of neuroblastoma (NBL) or ganglioneuroblastoma (nodular) verified by tumor pathology analysis or demonstration of clumps of tumor cells in bone marrow with elevated urinary catecholamines
-
Newly diagnosed, high risk neuroblastoma (HRNBL) defined as one of the following:
- Any age with International Neuroblastoma Risk Group (INRG) Stage L2, MS, or M and MYCN amplification
- Age ≥ 547 days and INRG stage M regardless of biologic features (clinical MYCN testing not required prior to enrollment)
- Any age initially diagnosed with INRG Stage L1 MYCN amplified NBL who have progressed to stage M without systemic chemotherapy
- Age ≥ 547 days of age initially diagnosed with INRG Stage L1, L2, or MS who have progressed to stage M without systemic chemotherapy (clinical MYCN testing not required prior to enrollment)
-
-
Patients must have a body surface area (BSA) ≥ 0.25 m^2
-
No prior anti-cancer therapy except as outlined below:
- Patients initially recognized to have high-risk disease treated with topotecan/cyclophosphamide initiated on an emergent basis and within allowed timing, and with consent
- Patients observed or treated with a single cycle of chemotherapy per a low or intermediate risk neuroblastoma regimen (e.g., as per ANBL0531, ANBL1232 or similar) for what initially appeared to be non-high-risk disease but subsequently found to meet the criteria
- Patients who received localized emergency radiation to sites of life threatening or function-threatening disease prior to or immediately after establishment of the definitive diagnosis
-
Human immunodeficiency virus (HIV) -infected patients on effective anti-retroviral therapy with undetectable viral load within 6 months are eligible for this trial
-
A serum creatinine based on age/sex as follows:
-
1 month to < 6 months: Male 0.4 mg/dL and female 0.4mg/dL
-
6 months to < 1 year: Male 0.5 mg/dL and female 0.5 mg/dL
-
1 to < 2 years: Male 0.6 mg/dL and female 0.6 mg/dL
-
2 to < 6 years: Male 0.8 mg/dL and female 0.8 mg/dL
-
6 to < 10 years: Male 1 mg/dL and female 1 mg/dL
-
10 to < 13 years: Male 1.2 mg/dL and female 1.2 mg/dL
-
13 to < 16 years: Male 1.5 mg/dL and female 1.4 mg/dL
-
≥ 16 years: Male 1.7 mg/dL and female 1.4 mg/dL
- The threshold creatinine values were derived from the Schwartz formula for estimating glomerular filtration rate (GFR) utilizing child length and stature data published by the Centers for Disease Control (CDC)
-
or a 24-hour urine creatinine clearance ≥ 70 mL/min/1.73 m^2 or
-
or a GFR ≥ 70 mL/min/1.73 m^2. GFR must be performed using direct measurement with a nuclear blood sampling method or direct small molecule clearance method (iothalamate or other molecule per institutional standard)
- Note: Estimated GFR (eGFR) from serum creatinine, cystatin C or other estimates are not acceptable for determining eligibility
-
-
Total bilirubin ≤ 1.5 x upper limit of normal (ULN) for age
-
Serum glutamic pyruvic transaminase (SGPT) (Alanine aminotransferase [ALT]) ≤ 10 x ULN*
- Note: For the purpose of this study, the ULN for SGPT (ALT) has been set to the value of 45 U/L
-
* Shortening fraction of ≥ 27% by echocardiogram, or
- Ejection fraction of ≥ 50% by echocardiogram or radionuclide angiogram
-
Ability to tolerate Peripheral Blood Stem Cell (PBSC) collection:
No known contraindication to PBSC collection. Examples of contraindications might be a weight or size less than the collecting institution finds feasible, or a physical condition that would limit the ability of the child to undergo apheresis catheter placement (if necessary) and/or the apheresis procedure
Exclusion Criteria:
- Patients who are 365-546 days of age with INRG Stage M and MYCN non-amplified NBL, irrespective of additional biologic features
- Patients ≥ 547 days of age with INRG Stage L2, MYCN non-amplified NBL, regardless of additional biologic features
- Patients with known bone marrow failure syndromes
- Patients on chronic immunosuppressive medications (e.g., tacrolimus, cyclosporine, corticosteroids) for reasons other than prevention/treatment of allergic reactions and adrenal replacement therapy are not eligible. Topical and inhaled corticosteroids are acceptable
- Patients with a primary immunodeficiency syndrome who require ongoing immune globulin replacement therapy
- Female patients who are pregnant since fetal toxicities and teratogenic effects have been noted for several of the study drugs. A pregnancy test is required prior to enrollment for female patients of childbearing potential
- Lactating females who plan to breastfeed their infants
- Sexually active patients of reproductive potential who have not agreed to use an effective contraceptive method for the duration of their study participation
- All patients and/or their parents or legal guardians must sign a written informed consent
- All institutional, food and drug administration (FDA), and National Cancer Institute (NCI) requirements for human studies must be met
Studieplan
Hur är studien utformad?
Designdetaljer
- Primärt syfte: Behandling
- Tilldelning: Randomiserad
- Interventionsmodell: Parallellt uppdrag
- Maskning: Ingen (Open Label)
Vapen och interventioner
Deltagargrupp / Arm |
Intervention / Behandling |
|---|---|
|
Aktiv komparator: Arm A (SOC treatment)
See detailed description |
Given IV
Andra namn:
Given IV
Andra namn:
Given IV
Andra namn:
Undergo bone marrow biopsy
Andra namn:
Given IV
Andra namn:
Given IV
Andra namn:
Undergo MRI
Andra namn:
Undergo ECHO
Andra namn:
Undergo MUGA
Andra namn:
Undergo bone marrow aspiration Given IV
Andra namn:
Undergo CT scan
Andra namn:
Given IV
Andra namn:
Undergo radiation therapy
Andra namn:
Undergo blood and urine sample collection
Andra namn:
Ancillary studies Given IV
Andra namn:
Given IV Given IV
Andra namn:
Given IV
Andra namn:
Undergo FDG PET
Andra namn:
Undergo stem cell infusion
Andra namn:
Given PO
Andra namn:
Undergo apheresis
Andra namn:
Undergo I-MIBG scan
Andra namn:
Given PO or via NG or G tube
Andra namn:
Undergo tumor resection surgery |
|
Experimentell: Arm B (Dinutuximab in induction)
See detailed description |
Given IV
Andra namn:
Given IV
Andra namn:
Given IV
Andra namn:
Undergo bone marrow biopsy
Andra namn:
Given IV
Andra namn:
Given IV
Andra namn:
Undergo MRI
Andra namn:
Undergo ECHO
Andra namn:
Undergo MUGA
Andra namn:
Undergo bone marrow aspiration Given IV
Andra namn:
Undergo CT scan
Andra namn:
Given IV
Andra namn:
Undergo radiation therapy
Andra namn:
Undergo blood and urine sample collection
Andra namn:
Ancillary studies Given IV
Andra namn:
Given IV Given IV
Andra namn:
Given IV
Andra namn:
Undergo FDG PET
Andra namn:
Undergo stem cell infusion
Andra namn:
Given PO
Andra namn:
Undergo apheresis
Andra namn:
Undergo I-MIBG scan
Andra namn:
Given PO or via NG or G tube
Andra namn:
Undergo tumor resection surgery |
Vad mäter studien?
Primära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Event free survival (EFS)
Tidsram: Up to 3 years
|
EFS time is calculated from time of randomization to Arms A or B to first episode of disease relapse or progression, second malignancy, or death, or until last contact if no event has occurred. |
Up to 3 years
|
Sekundära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
End of Induction (EOI) response rate
Tidsram: From randomization to end of extended Induction, up to 12 months
|
The response rate will be calculated among all evaluable patients at end of Induction. Responders are defined as patients who achieve a >= partial response per the revised 2017 International Neuroblastoma Response Criteria (INRC) |
From randomization to end of extended Induction, up to 12 months
|
|
Overall survival (OS)
Tidsram: Up to 3 years
|
OS time is calculated from time of randomization to Arms A or B until death, or until last contact if patient is alive. |
Up to 3 years
|
|
Incidence of adverse events
Tidsram: Up to 2 years
|
The proportion of patients with at least one grade 3 or higher non-hematologic toxicity or grade 4 or higher hematologic toxicity during protocol therapy, graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events version 5.0, will be reported. |
Up to 2 years
|
|
GD2 expression
Tidsram: Up to 12 months
|
Dinutuximab binding to pre-therapy patient tumor samples will be measured and categorized as high or low. |
Up to 12 months
|
Andra resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Association between tumor and host factors and outcomes
Tidsram: Up to 10 years
|
A series of univariate and multivariate Cox proportional hazards (for EFS and OS) and logistic regression (for responders vs. non-responders) models will be fit for patients in Arms A and B to evaluate the relationship between tumor and host factors (including tumor ALK and other somatic mutations, copy-number aberrations, gene fusions, gene expression, and pathogenic germline variants) and chemo-immunotherapy during Induction with outcome. |
Up to 10 years
|
|
Circulating biomarkers and markers of minimal residual disease
Tidsram: Up to 10 years
|
Will be assessed by comparing the proportion of patients with detectable vs. non-detectable tumor markers (including circulating tumor deoxyribonucleic acid, circulating free DNA, circulating tumor cells, and immune function profiling) between Arms A and B during and after induction and post-consolidation therapy using chi-squared tests at each individual time point, and Cochran's Q across time points to determine if there is a consistent difference in proportions between arms across time. In addition, the tumor markers will be analyzed as continuous variables using longitudinal data analysis methodology such as mixed effects models or generalized estimating equations as appropriate. |
Up to 10 years
|
|
Patterns of failure
Tidsram: Up to 10 years
|
The impact of early or late chemoimmunotherapy during Induction on the probability of the involvement of a specific disease site at first relapse will be evaluated using Fisher's exact test. |
Up to 10 years
|
|
Effect of telomere maintenance mechanisms
Tidsram: Up to 10 years
|
A series of univariate and multivariate Cox proportional hazards (for EFS and OS) and logistic regression (for responders vs. non-responders) models will be fit for patients in arms A and B to evaluate the relationship between telomere maintenance mechanism and chemoimmunotherapy during Induction with outcome. Patients will be classified into 3 groups by telomere maintenance mechanism (TMM) based on messenger ribonucleic acid expression of TERT and analysis of telomeric DNA C-circles: telomerase (TERT) positive, alternative of lengthening of telomeres (ALT) positive, or no identified TMM. |
Up to 10 years
|
|
Functional and quality of life outcomes
Tidsram: At serial time points during Induction, Extended Induction, Post-Consolidation, and at the end of therapy
|
Will descriptively summarize and compare the total Memorial Symptom Assessment Scale scores, total sub-domain scores, and individual symptom scores between patients randomized to receive dinutuximab during Induction (Arm B) to those of patients randomized to standard Induction (Arm A). |
At serial time points during Induction, Extended Induction, Post-Consolidation, and at the end of therapy
|
|
Adequacy of diagnostic biopsy specimens
Tidsram: At time of tissue collection
|
Will be evaluated by descriptively comparing the successful delineation of histologic classification, MYCN amplification status, and ALK status via the traditional method of obtaining tissue for diagnosis, open surgical biopsy, versus the less invasive percutaneous core needle biopsy. |
At time of tissue collection
|
|
Associations between family-reported adverse social determinants of health and both clinical outcomes and biology
Tidsram: Up to 10 years
|
Kaplan-Meier curves of EFS and OS will be generated and used to calculate 3-year EFS and OS estimates. Associations between social determinants of health (SDOH) and survival outcomes and time to receipt of dinutuximab will be evaluated with univariate and multivariate Cox proportional hazard models. Log-binomial regression will be used to estimate risk ratios and 95% CI for the occurrence of dinutuximab consent to randomization and therapy receipt by SDOH exposure. Effect modification of outcomes as a function of poverty, stratified by race/ethnicity, will be explored. |
Up to 10 years
|
|
Develop and validate deep learning predictors of Induction response (imaging objective)
Tidsram: At diagnosis, EOI, during Extended Induction, and end of Extended Induction
|
Scans will be given as input to a convolutional neural network trained to predict EOI response. |
At diagnosis, EOI, during Extended Induction, and end of Extended Induction
|
|
Compare institutional versus central determination of overall response, individual response components, and PEIR and GEIR determination (imaging objective)
Tidsram: Up to 10 years
|
Will be assessed by calculating the percentage of patients receiving the same EOI institutional and centrally reviewed determination of overall response, individual response components (primary tumor, soft tissue and bone metastatic disease, and bone marrow metastatic disease), and PEIR and GEIR. In addition, Cohen's kappa will be calculated to evaluate the concordance in each of these response measures. |
Up to 10 years
|
|
Incidence of late toxicities
Tidsram: Up to 10 years
|
Will be addressed by calculating the proportion of treated patients with each late effect, including but not limited to impaired organ function, neuropsychiatric toxicity, and secondary malignancy. A 95% confidence interval will be placed on each proportion. |
Up to 10 years
|
|
Reduced dose radiotherapy to the primary site clinical target volume (CTV) in patients with complete response of the primary site at EOI results in comparable local control relative to historical cohorts
Tidsram: Up to 10 years
|
The cumulative incidence of local progression (CILP) in patients with complete response of the primary site at EOI and GEIR on this study will be compared to the CILP rate of 11.2±1.8% observed on ANBL0532 using Gray's test. |
Up to 10 years
|
|
Post-transplant complications
Tidsram: Up to 100 days post-transplant
|
Will be evaluated by calculating the incidence of endothelial injury complications and non-relapse mortality within 100 days of transplant, transplant-associated thrombotic microangiopathy (TA-TMA), severe TA-TMA, and sinusoidal obstruction syndrome (SOS) on Arms A and B and comparing between arms with a chi-squared test. The impact of TA-TMA occurrence on the timing or exclusion of subsequent therapy and interventions utilized to treat the TA-TMA, and associations with outcomes (EFS and OS) will be assessed. |
Up to 100 days post-transplant
|
|
Associations between end of induction (EOI) response and individual response components
Tidsram: Up to 10 years
|
Log-rank tests will be used to explore the association between EOI response (using both the revised INRC and GEIR/PEIR classification) and individual response components (primary tumor, soft tissue and bone metastatic disease, and bone marrow metastatic disease) with outcome (EFS and OS). |
Up to 10 years
|
|
Changes in image-defined risk factors (IDRF)
Tidsram: Up to 10 years
|
The proportion of patients in the analytic cohort for whom each particular IDRF and also the presence of any IDRF is absent prior to surgical resection will be computed. McNemar's test for paired observations will be applied to determine whether there is a difference in the proportion of each IDRF and any IDRF present before and after initial therapy, and conditional logistic regression will be used to compare between treatment arms A and B. The IDRF status after initial therapy and whether there has been a change from diagnosis will be associated with surgical outcome (complete vs. incomplete resection, presence or absence of surgical complications) using chi-squared tests, and compared between treatment arms A and B with the Cochran-Mantel-Haenszel test. The association of IDRF status with presence or absence of local failure after primary tumor resection will also be evaluated using a chi-squared test, and compared between treatment arms A and B with the Cochran-Mantel-Haenszel. |
Up to 10 years
|
Samarbetspartners och utredare
Sponsor
Utredare
- Huvudutredare: Sara M Federico, Children's Oncology Group
Studieavstämningsdatum
Studera stora datum
Studiestart (Faktisk)
Primärt slutförande (Beräknad)
Avslutad studie (Beräknad)
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Faktisk)
Uppdateringar av studier
Senaste uppdatering publicerad (Faktisk)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Ytterligare relevanta MeSH-villkor
- Neoplasmer
- Neoplasmer efter histologisk typ
- Neoplasmer, körtel och epitel
- Neoplasmer, neuroepitelial
- Neuroektodermala tumörer
- Neoplasmer, könsceller och embryonala
- Neoplasmer, nervvävnad
- Neuroektodermala tumörer, primitiva, perifera
- Neuroektodermala tumörer, primitiva
- Neuroblastom
- Ganglioneuroblastom
- Organisation och administration
- Administration
- Aminosyror, peptider och proteiner
- Organiska kemikalier
- Heterocykliska föreningar, 1-ring
- Heterocykliska föreningar
- Heterocykliska föreningar, 2-ring
- Heterocykliska föreningar, smältring
- Undersökningstekniker
- Terapeutik
- Kliniska laboratorietekniker
- Diagnostiska tekniker och procedurer
- Diagnos
- Kirurgiska ingrepp, operativ
- Azoler
- Cytologiska tekniker
- Cytodiagnos
- Retinoider
- Karotenoider
- Polyener
- Alkener
- Kolväten, acyklisk
- Kolväten
- Cyklohexener
- Cyklohexaner
- Cykloparaffiner
- Kolväten, alicyklisk
- Kolväten, cykliska
- Terpener
- Pigment, biologiska
- Biologiska faktorer
- Kolhydrater
- Fysiska fenomen
- Camptotecin
- Alkaloider
- Podofyllotoxin
- Tetrahydronaftaler
- Naftalar
- Polycykliska aromatiska kolväten
- Kolväten, aromatisk
- Polycykliska föreningar
- Glukosider
- Glykosider
- Dacarbazin
- Triazenes
- Imidazoler
- Transplantation
- Förenad
- Oorganiska kemikalier
- Klorföreningar
- Kväveföreningar
- Koordinationskomplex
- Aminosyror
- Element
- Metaller
- Diagnostiska tekniker, kirurgiska
- Kemitekniker, analytiska
- Spektrumanalys
- Fosforamidsen
- Kväve senapsföreningar
- Senapsföreningar
- Kolväten, halogenerad
- Fosforamider
- Organofosforföreningar
- Metaller, tunga
- Vinca alkaloider
- Secologanin tryptaminalkaloider
- Indolalkaloider
- Indolizidiner
- Indoliziner
- Anthracykliner
- Naftakener
- Aminoglykosider
- Platinaföreningar
- Daunorubicin
- Övergångselement
- Celltransplantation
- Cell- och vävnadsbaserad terapi
- Biologisk behandling
- Cytapheres
- Blodkomponent
- Leukocytreduktionsförfaranden
- Cellseparation
- Fenylalanin
- Aminosyror, aromatiska
- Aminosyror, cykliska
- Sjukhusadministration
- Administration
- Trietylenefosforamid
- Aziridiner
- Aziriner
- Urologiska kirurgiska ingrepp
- Urogenital kirurgiska ingrepp
- Temozolomid
- Irinotekan
- Cyklofosfamid
- Melphalan
- Etoposid
- Karboplatin
- Doxorubicin
- Vincristine
- Cisplatin
- Isotretinoin
- Thiotepa
- Topotecan
- 1,2-diaminocyklohexanplatina II-citrat
- Strålbehandling
- Strålning
- Biopsi
- Provhantering
- Magnetresonansspektroskopi
- Platina
- dinutuximab
- Stamcellstransplantation
- Hematopoietisk stamcellstransplantation
- Leukaferes
- Kärnmedicinavdelning, sjukhus
- Transuretral resektion av urinblåsan
Andra studie-ID-nummer
- NCI-2023-08530
- U10CA180886 (U.S.S. NIH-anslag/kontrakt)
- NCI-2023-08530 (Registeridentifierare: CTRP (Clinical Trial Reporting Program))
- ANBL2131 (Annan identifierare: CTEP)
- ANBL2131 (Annan identifierare: Children's Oncology Group)
Plan för individuella deltagardata (IPD)
Planerar du att dela individuella deltagardata (IPD)?
IPD-planbeskrivning
"NCI is committed to sharing data in accordance with NIH policy. For more details on how clinical trial data is shared, access the link to the NIH data sharing policy page."
Läkemedels- och apparatinformation, studiedokument
Studerar en amerikansk FDA-reglerad läkemedelsprodukt
Studerar en amerikansk FDA-reglerad produktprodukt
produkt tillverkad i och exporterad från U.S.A.
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .